A
April K.S. Salama
Researcher at Duke University
Publications - 130
Citations - 9254
April K.S. Salama is an academic researcher from Duke University. The author has contributed to research in topics: Ipilimumab & Melanoma. The author has an hindex of 32, co-authored 111 publications receiving 6976 citations. Previous affiliations of April K.S. Salama include Durham University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Michael A. Postow,Jason Chesney,Anna C. Pavlick,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Gerald P. Linette,Nicolas Meyer,Jeffrey K. Giguere,Sanjiv S. Agarwala,Montaser Shaheen,Marc S. Ernstoff,David R. Minor,April K.S. Salama,Matthew H. Taylor,Patrick A. Ott,Linda Rollin,Christine Horak,Paul Gagnier,Jedd D. Wolchok,F. Stephen Hodi +20 more
TL;DR: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipILimumab monotherapy.
Journal ArticleDOI
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas,Igor Puzanov,Reinhard Dummer,Dirk Schadendorf,Omid Hamid,Caroline Robert,F. Stephen Hodi,Jacob Schachter,Anna C. Pavlick,Karl D. Lewis,Lee D. Cranmer,Christian U. Blank,Steven J. O'Day,Paolo A. Ascierto,April K.S. Salama,Kim Margolin,Carmen Loquai,Thomas Eigentler,Tara C. Gangadhar,Matteo S. Carlino,Sanjiv S. Agarwala,Stergios J. Moschos,Jeffrey A. Sosman,Simone M. Goldinger,Ronnie Shapira-Frommer,Rene Gonzalez,John M. Kirkwood,Jedd D. Wolchok,Alexander M.M. Eggermont,Xiaoyun Nicole Li,Wei Zhou,Adriane M Zernhelt,Joy Lis,Scot Ebbinghaus,S. Peter Kang,Adil Daud +35 more
TL;DR: In this article, the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma were compared.
Journal ArticleDOI
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi,Jason Chesney,Anna C. Pavlick,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Gerald P. Linette,Nicolas Meyer,Jeffrey K. Giguere,Sanjiv S. Agarwala,Montaser Shaheen,Marc S. Ernstoff,David R. Minor,April K.S. Salama,Matthew H. Taylor,Patrick A. Ott,Christine Horak,Paul Gagnier,Joel Jiang,Jedd D. Wolchok,Michael A. Postow +20 more
TL;DR: 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma and the proportion of patients with BRAFV600 wild-type melanoma achieving an investigator-assessed objective response is reported.
Journal ArticleDOI
A review of cancer immunotherapy toxicity.
TL;DR: This review will focus on the toxicities of checkpoint inhibitors and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management.
Journal ArticleDOI
Cutaneous melanoma, version 2.2019
Daniel G. Coit,John A. Thompson,Mark R. Albertini,Christopher A. Barker,William E. Carson,Carlo M. Contreras,Gregory A. Daniels,Dominick J. DiMaio,Ryan C. Fields,Martin D. Fleming,Morganna Freeman,Anjela Galan,Brian R. Gastman,Valerie Guild,Douglas B. Johnson,Richard W. Joseph,Julie R. Lange,Sameer K. Nath,Anthony J. Olszanski,Patrick A. Ott,Aparna Priyanath Gupta,Merrick I. Ross,April K.S. Salama,Joseph J. Skitzki,Jeffrey A. Sosman,Susan M. Swetter,Kenneth K. Tanabe,Evan Wuthrick,Nicole R. McMillian,Anita M. Engh +29 more
TL;DR: The data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease are summarized.